CD20 POSITIVE NON HODGKIN LYMPHOMA

Clinical trials for CD20 POSITIVE NON HODGKIN LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new CD20 POSITIVE NON HODGKIN LYMPHOMA trials appear

Sign up with your email to follow new studies for CD20 POSITIVE NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New lymphoma drug trial ends early after just 7 patients

Disease control Terminated

This early-stage study tested a new drug called CPO107 in people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find the safest dose and check for side effects. Only 7 people took part before the study was stopped early.

Matched conditions: CD20 POSITIVE NON HODGKIN LYMPHOMA

Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control

Last updated May 17, 2026 06:15 UTC

CD20 POSITIVE NON HODGKIN LYMPHOMA

Get alerted when new CD20 POSITIVE NON HODGKIN LYMPHOMA trials appear

New lymphoma drug trial ends early after just 7 patients